Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 13/20 | 0.57 |
| ▸ | WNT3A | P56704 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371204 | 0.89 | MET (0.58) | METCSNK1DWNT3A | |
| SCHEMBL4373367 | 0.85 | MET (0.79) | METCSNK1DWNT3A | |
| SCHEMBL4372035 | 0.85 | MET (0.72) | METCSNK1DWNT3A | |
| SCHEMBL371580 | 0.82 | MET (1.00) | METCSNK1DWNT3A | |
| SCHEMBL4376852 | 0.78 | WNT3A (0.68) | METCSNK1DWNT3A | |
| SCHEMBL2189472 | 0.78 | MET (0.87) | METCSNK1DWNT3A | |
| SCHEMBL13587173 | 0.76 | MET (0.89) | METCSNK1DWNT3A | |
| SCHEMBL4914800 | 0.76 | CSNK1D (0.87) | CSNK1DWNT3A | |
| SCHEMBL4372524 | 0.74 | MET (0.67) | MET | |
| SCHEMBL13587172 | 0.74 | WNT3A (0.67) | METCSNK1DWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | AMGEN INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | HGF, MET, HGFAC | MET 2/4885CSNK1D 1568/4885WNT3A 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.